Polycystic Ovarian Syndrome Treatment Market by Drug Class (Insulin Sensitizing Agent, Oral Contraceptive, Antiandrogens, Anti-Obesity Drugs, and Others), and Distribution Channel (Hospital Pharmacy, Drug Store & Retail Pharmacy, and Online Providers): Global Opportunity Analysis and Industry Forecast, 2019–2026

January 2020 | 217 pages | ID: PB16963FDAA0EN
Allied Market Research

Abstracts

The global polycystic ovarian syndrome treatment market was valued at $2,902 million in 2018, and is projected to reach $4,184 million by 2026, registering a CAGR of 4.7% from 2019 to 2026.

Polycystic ovary syndrome or PCOS is a hormonal disorder that is common among women of childbearing age. PCOS causes infrequent or prolonged menstrual cycle or excess male hormone levels. Presently, there is no cure for PCOS, however, medications are used to regulate menstrual cycle and manage symptoms of PCOS.

The polycystic ovarian syndrome treatment market is expected to experience a significant growth during the forecast period, owing to increase in prevalence of PCOS, rise in awareness among the patient population about PCOS, and increase in popularity of combination therapy drives the market growth. In addition, easy accessibility to PCOS therapeutics, rise in demand for PCOS medication, and technological advancements for detection of PCOS influence the market growth. However, lack of approved therapeutics and unknown etiology and pathophysiology of PCOS is anticipated to hamper the market growth.

The global polycystic ovarian syndrome treatment market is segmented on the basis of drug class, distribution channel, and region. Based on drug class, it is classified as insulin sensitizing agent, oral contraceptive, antiandrogens, anti-obesity drugs, and others. According to distribution channel, it is categorized as hospital pharmacies, drug stores & retail pharmacies, and online providers . Region wise, it is studied across North America (U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (China, Japan, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, Saudi Arabia, South Africa, and rest of LAMEA).

KEY BENEFITS FOR STAKEHOLDERS

• The study provides an in-depth analysis of the market along with the current trends and future estimations to elucidate the imminent investment pockets.
• It offers a quantitative analysis from 2018 to 2026, which is expected to enable the stakeholders to capitalize on the prevailing market opportunities.
• A comprehensive analysis of all the geographical regions is provided to determine the existing opportunities.
• The profiles and growth strategies of the key players are thoroughly analyzed to understand the competitive outlook of the global market.

KEY MARKET SEGMENTS

By Drug Class

• Insulin Sensitizing Agent
• Oral Contraceptive
• Antiandrogens
• Anti-Obesity Drugs
• Others

By Distribution Channel

• Hospital Pharmacies
• Drug Stores & Retail Pharmacies
• Online Providers

By Region

• North America
• U.S.
• Canada
• Mexico
• Europe
• Germany
• France
• UK
• Italy
• Spain
• Rest of Europe
• Asia-Pacific
• Japan
• China
• Australia
• India
• South Korea
• Rest of Asia-Pacific
• LAMEA
• Brazil
• Saudi Arabia
• South Africa
• Rest of LAMEA

LIST OF KEY PLAYERS PROFILED IN THE REPORT

• Allergan plc.
• AstraZeneca plc
• Bayer AG
• Bristol-Myers Squibb Company
• Johnson and Johnson
• Mylan N.V.
• Novartis AG
• Pfizer Inc.
• SANOFI
• Teva Pharmaceutical Industries

LIST OF OTHER PLAYERS IN THE VALUE CHAIN (These players are not profiled in the report. The same will be included on request.)

• Merck KGaA
• Ferring BV

Contents

CHAPTER 1: INTRODUCTION

1.1. Report Description
1.2. Key Benefits For Stakeholders
1.3. Key Market Segments
  1.3.1. List of Key Players Profiled In The Report
1.4. Research Methodology
  1.4.1. Secondary Research
  1.4.2. Primary Research
  1.4.3. Analyst Tools And Models

CHAPTER 2: EXECUTIVE SUMMARY

2.1. Key Findings of The Study
2.2. Key Findings
  2.2.1. Top Investment Pockets
  2.2.2. Market Player Positioning, 2018
2.3. Cxo Perspective

CHAPTER 3: MARKET OVERVIEW

3.1. Market Definition And Scope
3.2. Key Forces Shaping Polycystic Ovarian Syndrome Treatment Industry/Market
  3.2.1. Moderate Power of Suppliers
  3.2.2. High Threat of New Entrants
  3.2.3. High Threat of Substitution
  3.2.4. Moderate Competitive Rivalry
  3.2.5. Moderate Bargaining Power of Buyers
3.3. Market Dynamics
  3.3.1. Drivers
    3.3.1.1. Increase In Prevalence of Pcos
    3.3.1.2. Increase In Number of Pipeline Drugs
    3.3.1.3. Surge In Healthcare Expenditure Worldwide
  3.3.2. Restraint
    3.3.2.1. Lack of Approved Therapeutics For Treatment of Pcos
  3.3.3. Opportunities
    3.3.3.1. Growth Opportunities In Emerging Markets
    3.3.3.2. Higher Number of Unmet Needs For Treatment of Pcos
  3.3.4. Impact Analysis

CHAPTER 4: POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET, BY DRUG CLASS

4.1. Overview
  4.1.1. Market Size And Forecast
4.2. Insulin Sensitizing Agent
  4.2.1. Key Market Trends And Opportunities
  4.2.2. Market Size And Forecast, By Region
  4.2.3. Market Analysis, By Country
4.3. Oral Contraceptive
  4.3.1. Key Market Trends And Opportunities
  4.3.2. Market Size And Forecast, By Region
  4.3.3. Market Analysis, By Country
4.4. Antiandrogens
  4.4.1. Key Market Trends And Opportunities
  4.4.2. Market Size And Forecast, By Region
  4.4.3. Market Analysis, By Country
4.5. Anti-Obesity Drugs
  4.5.1. Key Market Trends And Opportunities
  4.5.2. Market Size And Forecast, By Region
  4.5.3. Market Analysis, By Country
4.6. Others
  4.6.1. Key Market Trends And Opportunities
  4.6.2. Market Size And Forecast, By Region
  4.6.3. Market Analysis, By Country

CHAPTER 5: POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET, BY END USER

5.1. Overview
  5.1.1. Market Size And Forecast
5.2. Hospitals Pharmacies
  5.2.1. Market Size And Forecast
  5.2.2. Market Analysis, By Country
5.3. Drug Stores And Retail Pharmacies
  5.3.1. Market Size And Forecast
  5.3.2. Market Analysis, By Country
5.4. Online Pharmacies
  5.4.1. Market Size And Forecast
  5.4.2. Market Analysis, By Country

CHAPTER 6: POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET, BY REGION

6.1. Overview
  6.1.1. Market Size And Forecast
6.2. North America
  6.2.1. Key Market Trends, Growth Factors, And Opportunities
  6.2.2. Market Size And Forecast, By Country
    6.2.2.1. U.S.
      6.2.2.1.1. U.S. Polycystic Ovarian Syndrome Treatment Market, By Drug Class
      6.2.2.1.2. U.S. Polycystic Ovarian Syndrome Treatment Market, By Distribution Channel
    6.2.2.2. Canada
      6.2.2.2.1. Canada Polycystic Ovarian Syndrome Treatment Market, By Drug Class
      6.2.2.2.2. Canada Polycystic Ovarian Syndrome Treatment Market, By Distribution Channel
    6.2.2.3. Mexico
      6.2.2.3.1. Mexico Polycystic Ovarian Syndrome Treatment Market, By Drug Class
      6.2.2.3.2. Mexico Polycystic Ovarian Syndrome Treatment Market, By Distribution Channel
  6.2.3. North America Market Size And Forecast, By Drug Class
  6.2.4. North America Polycystic Ovarian Syndrome Treatment Market, By Distribution Channel
6.3. Europe
  6.3.1. Key Market Trends, Growth Factors, And Opportunities
  6.3.2. Market Size And Forecast, By Country
    6.3.2.1. Germany
      6.3.2.1.1. Germany Polycystic Ovarian Syndrome Treatment Market, By Drug Class
      6.3.2.1.2. Germany Polycystic Ovarian Syndrome Treatment Market, By Distribution Channel
    6.3.2.2. France
      6.3.2.2.1. France Polycystic Ovarian Syndrome Treatment Market, By Drug Class
      6.3.2.2.2. France Polycystic Ovarian Syndrome Treatment Market, By Distribution Channel
    6.3.2.3. Uk
      6.3.2.3.1. Uk Polycystic Ovarian Syndrome Treatment Market, By Drug Class
      6.3.2.3.2. Uk Polycystic Ovarian Syndrome Treatment Market, By Distribution Channel
    6.3.2.4. Italy
      6.3.2.4.1. Italy Polycystic Ovarian Syndrome Treatment Market, By Drug Class
      6.3.2.4.2. Italy Polycystic Ovarian Syndrome Treatment Market, By Distribution Channel
    6.3.2.5. Spain
      6.3.2.5.1. Spain Polycystic Ovarian Syndrome Treatment Market, By Drug Class
      6.3.2.5.2. Spain Polycystic Ovarian Syndrome Treatment Market, By Distribution Channel
    6.3.2.6. Rest of Europe
      6.3.2.6.1. Rest of Europe Polycystic Ovarian Syndrome Treatment Market, By Drug Class
      6.3.2.6.2. Rest of Europe Polycystic Ovarian Syndrome Treatment Market, By Distribution Channel
  6.3.3. Europe Market Size And Forecast, By Drug Class
  6.3.4. Europe Polycystic Ovarian Syndrome Treatment Market, By Distribution Channel
6.4. Asia-Pacific
  6.4.1. Key Market Trends, Growth Factors, And Opportunities
  6.4.2. Market Size And Forecast, By Country
    6.4.2.1. Japan
      6.4.2.1.1. Japan Polycystic Ovarian Syndrome Treatment Market, By Drug Class
      6.4.2.1.2. Japan Polycystic Ovarian Syndrome Treatment Market, By Distribution Channel
    6.4.2.2. China
      6.4.2.2.1. China Polycystic Ovarian Syndrome Treatment Market, By Drug Class
      6.4.2.2.2. China Polycystic Ovarian Syndrome Treatment Market, By Distribution Channel
    6.4.2.3. Australia
      6.4.2.3.1. Australia Polycystic Ovarian Syndrome Treatment Market, By Drug Class
      6.4.2.3.2. Australia Polycystic Ovarian Syndrome Treatment Market, By Distribution Channel
    6.4.2.4. India
      6.4.2.4.1. India Polycystic Ovarian Syndrome Treatment Market, By Drug Class
      6.4.2.4.2. India Polycystic Ovarian Syndrome Treatment Market, By Distribution Channel
    6.4.2.5. South Korea
      6.4.2.5.1. South Korea Polycystic Ovarian Syndrome Treatment Market, By Drug Class
      6.4.2.5.2. South Korea Polycystic Ovarian Syndrome Treatment Market, By Distribution Channel
    6.4.2.6. Rest of Asia-Pacific
      6.4.2.6.1. Rest of Asia-Pacific Polycystic Ovarian Syndrome Treatment Market, By Drug Class
      6.4.2.6.2. Rest of Asia-Pacific Polycystic Ovarian Syndrome Treatment Market, By Distribution Channel
  6.4.3. Asia-Pacific Market Size And Forecast, By Drug Class
  6.4.4. Asia-Pacific Polycystic Ovarian Syndrome Treatment Market, By Distribution Channel
6.5. Lamea
  6.5.1. Key Market Trends, Growth Factors, And Opportunities
  6.5.2. Market Size And Forecast, By Country
    6.5.2.1. Brazil
      6.5.2.1.1. Brazil Polycystic Ovarian Syndrome Treatment Market, By Drug Class
      6.5.2.1.2. Brazil Polycystic Ovarian Syndrome Treatment Market, By Distribution Channel
    6.5.2.2. Saudi Arabia
      6.5.2.2.1. Saudi Arabia Polycystic Ovarian Syndrome Treatment Market, By Drug Class
      6.5.2.2.2. Saudi Arabia Polycystic Ovarian Syndrome Treatment Market, By Distribution Channel
    6.5.2.3. South Africa
      6.5.2.3.1. South Africa Polycystic Ovarian Syndrome Treatment Market, By Drug Class
      6.5.2.3.2. South Africa Polycystic Ovarian Syndrome Treatment Market, By Distribution Channel
    6.5.2.4. Rest of Lamea
      6.5.2.4.1. Rest of Lamea Polycystic Ovarian Syndrome Treatment Market, By Drug Class
      6.5.2.4.2. Rest of Lamea Polycystic Ovarian Syndrome Treatment Market, By Distribution Channel
  6.5.3. Lamea Market Size And Forecast, By Drug Class
  6.5.4. Lamea Polycystic Ovarian Syndrome Treatment Market, By Distribution Channel

CHAPTER 7: COMPANY PROFILES

7.1. Allergan Plc
  7.1.1. Company Overview
  7.1.2. Company Snapshot
  7.1.3. Operating Business Segments
  7.1.4. Product Portfolio
  7.1.5. Business Performance
7.2. Astrazeneca Plc
  7.2.1. Company Overview
  7.2.2. Company Snapshot
  7.2.3. Operating Business Segments
  7.2.4. Product Portfolio
  7.2.5. Business Performance
7.3. Bayer Ag.
  7.3.1. Company Overview
  7.3.2. Operating Business Segments
  7.3.3. Product Portfolio
  7.3.4. Business Performance
7.4. Bristol-Myers Squibb Company
  7.4.1. Company Overview
  7.4.2. Company Snapshot
  7.4.3. Operating Business Segments
  7.4.4. Product Portfolio
  7.4.5. Business Performance
7.5. Johnson And Johnson
  7.5.1. Company Overview
  7.5.2. Company Snapshot
  7.5.3. Operating Business Segments
  7.5.4. Product Portfolio
  7.5.5. Business Performance
7.6. Mylan N.V
  7.6.1. Company Overview
  7.6.2. Company Snapshot
  7.6.3. Operating Business Segments
  7.6.4. Product Portfolio
  7.6.5. Business Performance
7.7. Novartis Ag
  7.7.1. Company Overview
  7.7.2. Company Snapshot
  7.7.3. Operating Business Segments
  7.7.4. Product Portfolio
  7.7.5. Business Performance
7.8. Pfizer Inc.
  7.8.1. Company Overview
  7.8.2. Company Snapshot
  7.8.3. Operating Business Segments
  7.8.4. Product Portfolio
  7.8.5. Business Performance
7.9. Sanofi
  7.9.1. Company Overview
  7.9.2. Company Snapshot
  7.9.3. Operating Business Segments
  7.9.4. Product Portfolio
  7.9.5. Business Performance
7.10. Teva Pharmaceutical Industries
  7.10.1. Company Overview
  7.10.2. Operating Business Segments
  7.10.3. Product Portfolio
  7.10.4. Business Performance
  7.10.5. Key Strategic Moves And Developments

List Of Tables

LIST OF TABLES

Table 01. Global Polycystic Ovarian Syndrome Treatment Market, By Drug Class, 2018–2026 ($Million)
Table 02. Insulin Sensitizing Agent Market, By Region, 2018–2026 ($Million)
Table 03. Oral Contraceptive Market, By Region, 2018–2026 ($Million)
Table 04. Antiandrogens Market, By Region, 2018–2026 ($Million)
Table 05. Anti-Obesity Drugs Market, By Region, 2018–2026 ($Million)
Table 06. Others Market, By Region, 2018–2026 ($Million)
Table 07. Global Polycystic Ovarian Syndrome Treatment Market, By End User, 2018–2026 ($Million)
Table 08. Polycystic Ovarian Syndrome Treatment Market For Hospitals Pharmacies, By Region, 2018–2026 ($Million)
Table 09. Polycystic Ovarian Syndrome Treatment Market For Drug Stores And Retail Pharmacies, By Region, 2018–2026 ($Million)
Table 10. Polycystic Ovarian Syndrome Treatment Market For Online Pharmacies, By Region, 2018–2026 ($Million)
Table 11. Polycystic Ovarian Syndrome Treatment Market Revenue, By Region, 2018–2026 ($Million)
Table 12. North America Polycystic Ovarian Syndrome Treatment Market, By Country, 2018–2026 ($Million)
Table 13. U.S. Polycystic Ovarian Syndrome Treatment Market, By Drug Class, 2018–2026
Table 14. U.S. Polycystic Ovarian Syndrome Treatment Market, By Distribution Channel, 2018–2026
Table 15. Canada Polycystic Ovarian Syndrome Treatment Market, By Drug Class, 2018–2026
Table 16. Canada Polycystic Ovarian Syndrome Treatment Market, By Distribution Channel, 2018–2026
Table 17. Mexico Polycystic Ovarian Syndrome Treatment Market, By Drug Class, 2018–2026
Table 18. Mexico Polycystic Ovarian Syndrome Treatment Market, By Distribution Channel, 2018–2026
Table 19. North America Polycystic Ovarian Syndrome Treatment Market, By Drug Class, 2018–2026
Table 20. North America Polycystic Ovarian Syndrome Treatment Market, By Distribution Channel, 2018–2026
Table 21. Europe Polycystic Ovarian Syndrome Treatment Market, By Country, 2018–2026 ($Million)
Table 22. Germany Polycystic Ovarian Syndrome Treatment Market, By Drug Class, 2018–2026
Table 23. Germany Polycystic Ovarian Syndrome Treatment Market, By Distribution Channel, 2018–2026
Table 24. France Polycystic Ovarian Syndrome Treatment Market, By Drug Class, 2018–2026
Table 25. France Polycystic Ovarian Syndrome Treatment Market, By Distribution Channel, 2018–2026
Table 26. Uk Polycystic Ovarian Syndrome Treatment Market, By Drug Class, 2018–2026
Table 27. Uk Polycystic Ovarian Syndrome Treatment Market, By Distribution Channel, 2018–2026
Table 28. Italy Polycystic Ovarian Syndrome Treatment Market, By Drug Class, 2018–2026
Table 29. Italy Polycystic Ovarian Syndrome Treatment Market, By Distribution Channel, 2018–2026
Table 30. Spain Polycystic Ovarian Syndrome Treatment Market, By Drug Class, 2018–2026
Table 31. Spain Polycystic Ovarian Syndrome Treatment Market, By Distribution Channel, 2018–2026
Table 32. Rest of Europe Polycystic Ovarian Syndrome Treatment Market, By Drug Class, 2018–2026
Table 33. Rest of Europe Polycystic Ovarian Syndrome Treatment Market, By Distribution Channel, 2018–2026
Table 34. Europe Polycystic Ovarian Syndrome Treatment Market, By Drug Class, 2018–2026
Table 35. Europe Polycystic Ovarian Syndrome Treatment Market, By Distribution Channel, 2018–2026
Table 36. Asia-Pacific Polycystic Ovarian Syndrome Treatment Market, By Country, 2018–2026 ($Million)
Table 37. Japan Polycystic Ovarian Syndrome Treatment Market, By Drug Class, 2018–2026
Table 38. Japan Polycystic Ovarian Syndrome Treatment Market, By Distribution Channel, 2018–2026
Table 39. China Polycystic Ovarian Syndrome Treatment Market, By Drug Class, 2018–2026
Table 40. China Polycystic Ovarian Syndrome Treatment Market, By Distribution Channel, 2018–2026
Table 41. Australia Polycystic Ovarian Syndrome Treatment Market, By Drug Class, 2018–2026
Table 42. Australia Polycystic Ovarian Syndrome Treatment Market, By Distribution Channel, 2018–2026
Table 43. India Polycystic Ovarian Syndrome Treatment Market, By Drug Class, 2018–2026
Table 44. India Polycystic Ovarian Syndrome Treatment Market, By Distribution Channel, 2018–2026
Table 45. South Korea Polycystic Ovarian Syndrome Treatment Market, By Drug Class, 2018–2026
Table 46. South Korea Polycystic Ovarian Syndrome Treatment Market, By Distribution Channel, 2018–2026
Table 47. Rest of Asia-Pacific Polycystic Ovarian Syndrome Treatment Market, By Drug Class, 2018–2026
Table 48. Rest of Asia-Pacific Polycystic Ovarian Syndrome Treatment Market, By Distribution Channel, 2018–2026
Table 49. Asia-Pacific Polycystic Ovarian Syndrome Treatment Market, By Drug Class, 2018–2026
Table 50. Asia-Pacific Polycystic Ovarian Syndrome Treatment Market, By Distribution Channel, 2018–2026
Table 51. Lamea Polycystic Ovarian Syndrome Treatment Market, By Country, 2018–2026 ($Million)
Table 52. Brazil Polycystic Ovarian Syndrome Treatment Market, By Drug Class, 2018–2026
Table 53. Brazil Polycystic Ovarian Syndrome Treatment Market, By Distribution Channel, 2018–2026
Table 54. Saudi Arabia Polycystic Ovarian Syndrome Treatment Market, By Drug Class, 2018–2026
Table 55. Saudi Arabia Polycystic Ovarian Syndrome Treatment Market, By Distribution Channel, 2018–2026
Table 56. South Africa Polycystic Ovarian Syndrome Treatment Market, By Drug Class, 2018–2026
Table 57. South Africa Polycystic Ovarian Syndrome Treatment Market, By Distribution Channel, 2018–2026
Table 58. Rest of Lamea Polycystic Ovarian Syndrome Treatment Market, By Drug Class, 2018–2026
Table 59. Rest of Lamea Polycystic Ovarian Syndrome Treatment Market, By Distribution Channel, 2018–2026
Table 60. Lamea Polycystic Ovarian Syndrome Treatment Market, By Drug Class, 2018–2026
Table 61. Lamea Polycystic Ovarian Syndrome Treatment Market, By Distribution Channel, 2018–2026
Table 62. Allergan: Company Snapshot
Table 63. Allergan: Operating Segments
Table 64. Allergan: Product Portfolio
Table 65. Astrazeneca: Company Snapshot
Table 66. Astrazeneca: Product Segments
Table 67. Astrazeneca: Product Portfolio
Table 68. Bayer.: Company Snapshot
Table 69. Bayer.: Operating Segments
Table 70. Bayer.: Product Portfolio
Table 71. Bms: Company Snapshot
Table 72. Bms: Operating Segments
Table 73. Bms: Product Portfolio
Table 74. J&J: Company Snapshot
Table 75. J&J: Operating Segments
Table 76. J&J: Product Portfolio
Table 77. Mylan: Company Snapshot
Table 78. Mylan: Operating Segments
Table 79. Mylan: Product Portfolio
Table 80. Novartis: Company Snapshot
Table 81. Novartis: Operating Segments
Table 82. Novartis: Product Portfolio
Table 83. Pfizer: Company Snapshot
Table 84. Pfizer: Operating Segments
Table 85. Pfizer: Product Portfolio
Table 86. Sanofi: Company Snapshot
Table 87. Sanofi: Operating Segments
Table 88. Sanofi: Product Portfolio
Table 89. Teva: Company Snapshot
Table 90. Teva: Product Portfolio

List Of Figures

LIST OF FIGURES

Figure 01. Top Investment Pockets
Figure 02. Market Player Positioning, 2018
Figure 03. Global Polycystic Ovarian Syndrome Treatment Market Segmentation
Figure 04. Impact Analysis
Figure 05. Comparative Analysis of Insulin Sensitizing Agent Market, By Country, 2018 & 2026 ($Million)
Figure 06. Comparative Analysis of Oral Contraceptive Market, By Country, 2018 & 2026 ($Million)
Figure 07. Comparative Analysis of Antiandrogens Market, By Country, 2018 & 2026 ($Million)
Figure 08. Comparative Analysis of Anti-Obesity Drugs Market, By Country, 2018 & 2026 ($Million)
Figure 09. Comparative Analysis of Others Market, By Country, 2018 & 2026 ($Million)
Figure 10. Comparative Analysis of Polycystic Ovarian Syndrome Treatment Market For Hospitals Pharmacies, By Country, 2018 & 2026 ($Million)
Figure 11. Comparative Analysis of Polycystic Ovarian Syndrome Treatment Market For Drug Stores And Retail Pharmacies, By Country, 2018 & 2026 ($Million)
Figure 12. Comparative Analysis of Polycystic Ovarian Syndrome Treatment Market For Online Pharmacies, By Country, 2018 & 2026 ($Million)
Figure 13. U.S. Polycystic Ovarian Syndrome Treatment Market, 2018–2026 ($Million)
Figure 14. Canada Polycystic Ovarian Syndrome Treatment Market, 2018–2026 ($Million)
Figure 15. Mexico Polycystic Ovarian Syndrome Treatment Market, 2018–2026 ($Million)
Figure 16. Germany Polycystic Ovarian Syndrome Treatment Market, 2018–2026 ($Million)
Figure 17. France Polycystic Ovarian Syndrome Treatment Market, 2018–2026 ($Million)
Figure 18. Uk Polycystic Ovarian Syndrome Treatment Market, 2018–2026 ($Million)
Figure 19. Italy Polycystic Ovarian Syndrome Treatment Market, 2018–2026 ($Million)
Figure 20. Spain Polycystic Ovarian Syndrome Treatment Market, 2018–2026 ($Million)
Figure 21. Rest of Europe Polycystic Ovarian Syndrome Treatment Market, 2018–2026 ($Million)
Figure 22. Japan Polycystic Ovarian Syndrome Treatment Market, 2018–2026 ($Million)
Figure 23. China Polycystic Ovarian Syndrome Treatment Market, 2018–2026 ($Million)
Figure 24. Australia Polycystic Ovarian Syndrome Treatment Market, 2018–2026 ($Million)
Figure 25. India Polycystic Ovarian Syndrome Treatment Market, 2018–2026 ($Million)
Figure 26. South Korea Polycystic Ovarian Syndrome Treatment Market, 2018–2026 ($Million)
Figure 27. Rest of Asia-Pacific Polycystic Ovarian Syndrome Treatment Market, 2018–2026 ($Million)
Figure 28. Brzil Polycystic Ovarian Syndrome Treatment Market, 2018–2026 ($Million)
Figure 29. Saudi Arabia Polycystic Ovarian Syndrome Treatment Market, 2018–2026 ($Million)
Figure 30. South Africa Polycystic Ovarian Syndrome Treatment Market, 2018–2026 ($Million)
Figure 31. Rest of Lamea Polycystic Ovarian Syndrome Treatment Market, 2018–2026 ($Million)
Figure 32. Allergan: Net Sales, 2016–2018 ($Million)
Figure 33. Allergan: Revenue Share By Region, 2018(%)
Figure 34. Astrazeneca: Net Sales, 2016–2018 ($Million)
Figure 35. Astrazeneca: Revenue Share By Region, 2018(%)
Figure 36. Bayer: Net Sales, 2016–2018 ($Million)
Figure 37. Bayer.: Revenue Share By Segment, 2018 (%)
Figure 38. Bayer.: Revenue Share By Region, 2018(%)
Figure 39. Bms: Net Sales, 2016–2018 ($Million)
Figure 40. Bms: Revenue Share By Region, 2018(%)
Figure 41. J&J: Net Sales, 2016–2018 ($Million)
Figure 42. J&J: Revenue Share By Segment, 2018 (%)
Figure 43. J&J: Revenue Share By Region, 2018(%)
Figure 44. Mylan: Net Sales, 2016–2018 ($Million)
Figure 45. Mylan: Revenue Share By Geography, 2018 (%)
Figure 46. Novartis: Net Sales, 2016–2018 ($Million)
Figure 47. Novartis: Revenue Share By Segment, 2018 (%)
Figure 48. Novartis: Revenue Share By Region, 2018(%)
Figure 49. Pfizer: Net Sales, 2016–2018 ($Million)
Figure 50. Pfizer: Revenue Share By Segment, 2018 (%)
Figure 51. Pfizer: Revenue Share By Region, 2018(%)
Figure 52. Sanofi: Net Sales, 2016–2018 ($Million)
Figure 53. Sanofi: Revenue Share By Segment, 2018 (%)
Figure 54. Sanofi: Revenue Share By Region, 2018(%)
Figure 55. Teva Pharmaceutical Industries: Net Sales, 2016–2018 ($Million)
Figure 56. Teva Pharmaceutical Industries: Revenue Share By Segments 2018 ($Million)